Meta-Analysis Treatment Hyperphosphatemia Chronic Renal Failure Based on Nano Lanthanum Hydroxide

In this study, our aim is to investigate the effect of lanthanum carbonate in chronic treatment renal failure complicated with hyperphosphatemia. Using methods with lanthanum carbonate, hyperphosphatemia, placebos, calcium carbonate, end-stage renal disease as keywords, we searched the Chinese Journal Full-text Database, Chinese sci-tech journal database, Wanfang Data knowledge service platform, web of science, PubMed, and other databases for literature quality; meta analysis was carried out after a subsequent evaluation. The meta analysis results showed a significant difference in the control of the blood phosphorus level between weighted mean difference WMD = -0.60, 95% CI: -0.75~-0.45, lanthanum carbonate and placebo; WMD = -0.01, 95% CI: -0.07~-0.05; the lanthanum carbonate and placebo had no significant difference in the control of the blood calcium levels after treatment; WMD = -29.75, 95% CI: -39.22 for the control of blood PIH level after treatment, indicating that the difference between lanthanum carbonate and placebo in the control of the parathyroid hormone (PTH) level was statistically significant. WMD=0.41, 95% CI: -0.48~0.34; the difference between the lanthanum carbonate and calcium carbonate in the control of the blood phosphorus level was statistically significant; WMD = 0.19, 95% CI: -0.25~0.13, lanthanum carbonate and calcium carbonate were statistically significant in blood control calcium level; WMD = 174.66, 95% CI: -150.86~150.46, lanthanum carbonate and calcium carbonate were statistically significant in the control of blood PIH level; the difference was statistically significant. Conclusion: Lanthanum carbonate can significantly reduce blood phosphorus and PIH complicated hyperphosphatemia, and has no significant effect on blood calcium, which is superior to calcium carbonate in effectiveness.